TLRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tilray is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some improving business signals, but the overall trend is still weak: the price is below key moving averages, analysts have mixed and recently lowered targets, and the company remains unprofitable. For an impatient investor who does not want to wait for a better entry, this is not an attractive long-term purchase at the current level.
TLRY is trading at 5.53 after a 2.12% regular-session decline and a slight -0.18% pre-market move. Momentum is mixed: MACD histogram is positive and expanding, but RSI_6 at 61.77 is only neutral-to-mildly bullish. The broader trend is still bearish because SMA_200 > SMA_20 > SMA_5, which confirms the stock remains in a downtrend. Near-term levels to watch are pivot 5.40, resistance 5.634 and 5.778, with support at 5.166 and 5.022. The stock trend model suggests modest upside probability over time, but nothing strong enough to override the bearish moving-average structure.
["International cannabis sales grew 73% year over year in Q3 2026.", "Adjusted EBITDA increased 19% year over year, showing better cost control.", "FDA reclassification to Schedule III may support medical research and improve long-term sentiment.", "Analyst upgrade from Roth Capital to Buy with a $10 target signals some improving confidence.", "Bullish options sentiment shows call-heavy positioning."]
["The stock is still down more than 90% over five years, reflecting deep long-term weakness.", "Overall revenue growth was only modest despite international strength.", "The company still reported a net loss of $25.2 million in the latest quarter.", "Recent analyst actions were mixed, with multiple target cuts from Canaccord, Alliance Global, and TD Cowen.", "Bearish moving averages confirm the broader trend remains down.", "No meaningful insider buying, hedge fund accumulation, or congress trading support was reported."]
Latest quarter: fiscal Q3 2026. Tilray reported modest overall revenue growth, with international cannabis sales up 73% year over year, and adjusted EBITDA up 19% year over year, which shows better operating efficiency. That said, the company still posted a net loss of $25.2 million, so the business is improving but not yet consistently profitable.
Analyst sentiment is mixed but slightly improved recently. On 2026-04-01, Roth Capital upgraded TLRY to Buy with a $10 target, citing stable core Canadian business, improving international operations, and better beverage trends. However, other firms cut targets: Canaccord lowered to C$9.50 and kept Hold, Alliance Global cut to $7 and stayed Neutral, and TD Cowen cut to $7 while keeping Buy. Overall, Wall Street is split: the pros see potential from operational improvement and regulatory upside, but the cons focus on weak financial quality, sector uncertainty, and target reductions.
